CirCode Biomed gains clearance from FDA for RNA drug HM2002
CirCode Biomed’s circular RNA drug HM2002 has received investigational new drug (IND) clearance from the US Food and Drug Administration…
Cardiovascular
-
-
HLS Therapeutics and Esperion partner to commercialise oral cardiovascular medicines
HLS Therapeutics has signed an agreement with Esperion Therapeutics for in-licensing and commercialising the oral cardiovascular medicines, Nexletol (bempedoic acid)…
-
Haya secures $65m in Series A funds to advance heart failure treatment
Haya Therapeutics has procured $65m in Series A funding to expedite the clinical development of HTX-001 for treating heart failure.…
-
UK MHRA authorises BridgeBio’s acoramidis for ATTR-CM
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for BridgeBio Pharma’s acoramidis under the name…
-
ACC 2025: GLP-1RAs may reduce incidence of AF/flutter and stroke in diabetic patients
At the American College of Cardiology’s 74th Annual Scientific Session in Chicago, results from a study by O’Neill and colleagues…
-
ACC 25: tirzepatide influences clinical trajectory of patients with HFpEF and obesity
At the American College of Cardiology’s 74th Annual Scientific Session in Chicago, further results and analyses were presented from the…
-
Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug
Novo Nordisk has signed a deal worth up to $1bn with Lexicon Pharmaceuticals for the exclusive global rights to LX9851,…
-
MSD makes licence agreement with Hengrui Pharma for Lp(a) inhibitor
MSD has entered an exclusive licence agreement with Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma) for the investigational oral small molecule lipoprotein(a)…
-
Alnylam challenges Pfizer and BridgeBio with FDA nod for ATTR-CM drug
Alnylam Pharmaceutical’s has secured US Food and Drug Administration (FDA) approval for Amvuttra (vutrisiran), expanding its use to treat transthyretin…
-
Genentech wins FDA approval for second stroke treatment
Genentech has secured a second marketed stroke therapy after the US Food and Drug Administration (FDA) approved a label expansion…
